Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/106230
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNatarajan, Jayaganesh V.en
dc.contributor.authorAng, Marcusen
dc.contributor.authorDarwitan, Anastasiaen
dc.contributor.authorChattopadhyay, Sujayen
dc.contributor.authorWong, Tina T.en
dc.contributor.authorVenkatraman, Subbu S.en
dc.date.accessioned2014-10-07T02:36:18Zen
dc.date.accessioned2019-12-06T22:06:57Z-
dc.date.available2014-10-07T02:36:18Zen
dc.date.available2019-12-06T22:06:57Z-
dc.date.copyright2012en
dc.date.issued2012en
dc.identifier.citationNatarajan, J. V., Ang, M., Darwitan, A., Chattopadhyay, S., Wong, T. T., & Venkatraman, S. S. (2012). Nanomedicine for glaucoma : liposomes provide sustained release of latanoprost in the eye. International journal of nanomedicine, 2012(7), 123-131.en
dc.identifier.issn1176-9114en
dc.identifier.urihttps://hdl.handle.net/10356/106230-
dc.description.abstractPurpose: To report the development and therapeutic evaluation of a liposomal nanocarrier for sustained release of latanoprost, in the rabbit eye. Methods: We fabricated latanoprost-loaded egg-phosphatidylcholine (EggPC) liposomes using the film hydration technique. The delivery vehicles were nano-sized (Z avg = 109 ± 18 nm), had a narrow poly dispersity index (PDI = 0.19 ± 0.04), and a very high loading efficiency (94% ± 5%). Based on in vitro data, we evaluated this formulation for lowering intraocular pressure (IOP) in rabbit eyes. Following a single subconjunctival injection of the latanoprost loaded formulation, the eyes were clinically monitored and the IOP recorded. Results: Latanoprost-loaded EggPC liposomes demonstrated a high drug/lipid mole ratio of 0.181, remained stable for at least 6 months on storage (4°C), and at least 1 month at 25°C. A slow and sustained release of 60% of latanoprost was achieved by 14 days in the in vitro release study. The same formulation demonstrated a greater sustained IOP lowering effect compared with daily administration of topical latanoprost beyond 90 days (4.8 ± 1.5 vs 2.5 ± 0.9 mmHg; P < 0.001). No signs of inflammation were evident in the eyes from slit-lamp examination analysis. Conclusion: The loading required for a long-term sustained delivery of latanoprost for up to 90 days in the rabbit eyes was achieved with EggPC liposomes. A single injection of latanoprost-loaded EggPC liposomes can lower the IOP for up to 90 days, with a greater IOP lowering effect than daily topical administration of latanoprost.en
dc.format.extent9 p.en
dc.language.isoenen
dc.relation.ispartofseriesInternational journal of nanomedicineen
dc.rights© 2012 Natarajan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.en
dc.subjectDRNTU::Science::Medicineen
dc.titleNanomedicine for glaucoma : liposomes provide sustained release of latanoprost in the eyeen
dc.typeJournal Articleen
dc.contributor.schoolSchool of Materials Science & Engineeringen
dc.description.versionPublished versionen
dc.identifier.urlhttp://www.dovepress.com/nanomedicine-for-glaucoma-liposomes-provide-sustained-release-of-latan-peer-reviewed-article-IJNen
item.grantfulltextopen-
item.fulltextWith Fulltext-
Appears in Collections:MSE Journal Articles
Files in This Item:
File Description SizeFormat 
IJN-25468-nanomedicine-for-glaucoma--liposomes-provide-sustained-relea_010412.pdf523.83 kBAdobe PDFThumbnail
View/Open

Page view(s) 20

457
Updated on Jul 26, 2021

Download(s) 20

249
Updated on Jul 26, 2021

Google ScholarTM

Check

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.